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Abstract: HIV-infected patients exhibit quantitative and qualitative defects in CD4 T cells, including having increased 
numbers of CD4+CD45R0+/CD45RA+ T cells, although it remains unclear how these cells arise. Here we demonstrate 
that gp120 treatment of activated but not resting primary human CD4 T cells decreases number of cells with single posi-
tive CD45R0+/CD45RA- effector memory phenotype while proportionally increasing the subset of cells with double posi-
tive CD45R0+/CD45RA+ mixed phenotype. We found that double positive CD45R0+/CD45RA+CD4 T cells preferen-
tially undergo apoptosis while single positive CD45R0+/CD45RA- and CD45R0-/CD45RA+ do not. Blocking gp120-
CD4 interaction with sCD4 or inhibition Lck activity reverses gp120 induced increase in double positive 
CD45R0+/CD45RA+CD4 T cells and subsequently diminishes the apoptosis of double positive CD45R0+/CD45RA+ 
cells. Altogether these data indicate that gp120 ligation of the CD4 receptor increases the number of double positive 
CD45R0+/CD45RA+ CD4 T cells which subsequently undergo apoptosis in a CD4 dependent manner. 
INTRODUCTION 
  One hallmark of HIV pathogenesis is a decline of CD4 T 
cell number that results from the death of both HIV-1 in-
fected CD4 T cells, as well as uninfected cells. Both HIV 
expressed proteins, as well as immune activation, contribute 
to this T cell death [1]. Immune activation leads to an in-
crease in T cell turnover from enhanced proliferation which 
in turn is associated with high rates of apoptosis [2, 3]. The 
magnitude of immune activation correlates with the level of 
HIV viremia [4]. Increased expression of immune activation 
markers (HLA-DR+, CD38+, CD45RO+, and CD95) also 
correlates with higher apoptosis rates of CD4 T cells [5]. 
Importantly, suppression of viral replication with HAART 
treatment reduces immune activation [6, 7], normalizes ex-
pression of activation markers, and decreases CD4 T cell 
apoptosis [8-10]. 
  As a result of chronic immune activation, central memory 
and naïve CD4 T cells are constantly recruited into the effec-
tor pool [11, 12] resulting in dramatic changes in populations 
of naïve, effector and central memory CD4 T cells [13]. The 
mechanisms of how the ratio of these CD4 T cells is altered 
during HIV infection are not completely understood. 
  In particular, chronic HIV infection results in an in-
creased number of CD4 T cells with a peculiar double posi-
tive CD45RO+/CD45RA+/CD25+CD4+ phenotype, and this 
subset is further increased following intermittent IL-2 ther-
apy [14]. The origin of this subset was previously ascribed to 
be transition phase of naïve CD45RO-/CD45RA+CD4 T 
cells transitioning to a memory CD45RO+/CD45RA-CD4 T 
cell phenotype [15]. Furthermore, HAART with IL-2 therapy 
selectively increases the number of activated CD4 T cell   
expressing CD45RO+/CD25+ [16]. Here we describe a 
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novel effect of HIV-1 gp120 signaling through CD4 result-
ing in altered CD45 isoform expression by CD4 T cells. 
MATERIALS AND METHODOLOGY 
Cell Culture and Reagents 
  This protocol was reviewed and approved by the Mayo 
institutional review board. CD4+
 T cells were isolated from 
the blood of healthy volunteer blood donors by using Ros-
setteSep CD4 enrichment cocktail (StemCell Technologies, 
Vancouver, British Columbia, Canada), producing 98% pure 
CD4+ T cells as determined by flow cytometry. CD4 T cells 
were maintained in RPMI 1640 supplemented with 10% fetal 
bovine serum (Invitrogen, Carlsbad, CA), 2 mM L-
glutamine, and antibiotics (penicillin 100 U/ml, streptomycin 
100 μg/ml) at 0.5x10
6 cells/ml. CD4+ T cells used in the 
various experiments were stimulated with PHA (1 μg/ml) for 
24 hours, and then cells were washed twice with RPMI 1640 
and maintained in media supplemented with 50 U/ml of IL-2 
for 48-72 hours. CD4 T cells were incubated with HIV-1 X4 
gp120IIIB (Immuno Diagnostics, Inc. Woburn, MA) or 
gp120 IIIB pretreated with soluble CD4 (1:2 ratio) (Immuno 
Diagnostics, Inc. Woburn, MA) at concentrations of 1 
μg/ml/2x10
6 cells for 24 hours at 37°C. AMD3100 (NIH 
AIDS Research and Reference program) was used at 2 μM 
for 30 minutes at 37°C. PP2 was purchased from CalBio-
chem (La Jolla, CA). Anti-CD4-PE, anti-CD25-FITC, anti-
CD69-PE, anti-CD4PerCP, anti-CD62L-PE, anti-CD45RO-
FITC, anti-CD45RA-PE-Cy-7, anti-HLA-DR-PE, Annex-
inV-Cy-5, AnnexinV-APC, IgG1-PE-Cy7, IgG2a-FITC, 
IgG1-PE and propidium iodine were purchased from BD 
Biosciences (San Jose, CA). 
Cell Death Analysis and Flow Cytometry 
  CD4 T cells were untreated or pre-incubated with spe-
cific inhibitors and stimulated with either BSA or with solu-
ble gp120IIIB (10μg/ml) overnight. The following day, cell 
death was analyzed by staining with AnnexinV-Cy-5 and 
propidium iodine following the manufacturer’s instructions 22    The Open Virology Journal, 2009, Volume 3  Trushin et al. 
from BD Biosciences (San Jose, CA). All experiments were 
performed at least three times. 
  T cell phenotyping studies were performed by using four-
color Flow analysis on FACSCanto cytometer and using 
FACSDiva 6.0 software. Briefly, 2x10
6 cells were resus-
pended in 200μl of PBS+0.5%BSA, stained with the indi-
cated primary conjugated antibodies for 20 minutes (anti-
CD45RO-FITC, anti-CD45RA-PE-Cy-7, anti-CD27 APC 
and anti-CD62L-PE), washed, fixed and then analyzed. In 
some cases, for analysis of cell death, cells were stained in 
binding buffer (140 mM NaCl, 10 mM HEPES/NaOH (pH 
7.4), 2.5 mM CaCl2) as described above except that anti-
CD62L-PE was substituted with AnnexinV-PE. 
RESULTS 
Gp120 Decreases CD45RO+ Memory Phenotype in Acti-
vated But Not Resting CD4 T cells 
  We and others have previously demonstrated that gp120 
induces death of resting CD4 T cell in a CXCR4-p38 de-
pendent manner [17]. However, the effect of gp120 on acti-
vated CD4 T cells is largely unknown. To examine the effect 
of gp120, resting (CD4+CD25-CD69-HLA-DR-) and acti-
vated (CD4+ CD25+CD69+HLA-DR+) primary human CD4 
T cells were treated with gp120 IIIB (10μg/ml) for 24 hours 
and then CD4 T cells were analyzed for CD45R0 and 
CD45RA expression by flow cytometry. As shown in Fig. 
(1A), gp120 treatment results in a 50% decrease in the subset 
of single positive CD45R0+/CD45RA- (31.85 + 0.63% with 
BSA, 13.80 + 3.73% with gp120, p=0.01) memory cells 
when activated but not resting CD4 T cells are treated with 
gp120 (34.25 + 1.1% with BSA, 28.95 + 1.96% with gp120, 
p=0.08). In parallel, there is a proportional increase in the 
subset of double positive CD45R0+/CD45RA+ mixed phe-
notype CD4+ T cells (Fig. 1B) as well as an increase in the 
proportion of Annexin-V positive CD4 T cells (Fig. 1C). 
While the increased apoptosis of resting cells following 
gp120 is due to CXCR4 signaling [17], the mechanisms by 
which gp120 causes death in activated cells are unknown. 
  The finding that gp120 treatment of activated cells in-
creases the lymphoid homing marker, CD27 (13.8% of total 
CD4 T cells) preferentially in double positive 
CD45R0+/CD45RA+ cells suggests that these cells might be 
the specific cell type which dies following gp120 treatment of 
activated CD4 T cells (Fig. 2A, B). We therefore measured 
absolute number and proportion of Annexin-V positivity of 
double positive CD45R0+/CD45RA+, single positive 
CD45R0-/CD45RA+ and CD45R0+/CD45RA- subsets by 
using four color flow cytometry analysis. First we observed 
that CD45RO+RA- proportion decreased (39.42 + 3.44% with 
BSA, 27.31 + 6.38% with gp120) while CD45RO+RA+ popu-
lation increased (35.97 + 2.70% with BSA, 49.42 + 10.05% 
with gp120), suggesting that the former transitioned to the 
latter (Fig. 3A). Next we observed that only double positive 
CD45R0+/CD45RA+ CD4 T cell subset contain a significant 
proportion of Annexin positive cells (~40%) in contrast to 
single positive CD45R0+/CD45RA- and CD45R0-/CD45RA+ 
subsets that do not (Fig. 3B). Therefore, gp120 signaling both 
 
Fig. (1). Gp120 decreases CD45RO+/CD45RA- memory phenotype in activated but not resting primary human CD4 T cells. (A and 
B) CD4+
 T cells (98% pure) were stimulated with PHA for 24 hours or left rested, and treated with either p120 (IIIB) (1μg/ml) or BSA con-
trol (1μg/ml) and analyzed for CD45RO and CD45RA (gated on CD4 population) by flow cytometry. (C) Resting and activated primary 
human CD4 T cells were treated with gp120 (IIIB) as above and analyzed for Annexin-V positive cells. Data is representative of three inde-
pendent experiments. 
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activates cells towards a double positive phenotype and subse-
quently promotes their apoptotic death. Of interest, these An-
nexin positive CD45R0+/CD45 RA+ cells are also CD27+. 
Altogether these results indicate that gp120 treatment of acti-
vated CD4 T cells result in decrease memory 
CD45R0+/CD45RA- CD4 T cells due to accumulation of 
CD45R0+/CD45RA+ /CD27+ T cell subset that subsequently 
and selectively undergo apoptosis. 
 
Fig. (2). Gp120 increases subset of CD27+/CD45RO+/CD4+ T 
cells. (A) Activated primary human CD4 T cells (98% pure) were 
treated with gp120 IIIIB and the expression of CD27 and CD45RA 
were analyzed by flow cytometry. (B) Pooled data from three inde-
pendent experiments. P values were determined by Student’s paired 
t test. 
Gp120 Stimulated Accumulation of CD45RO+/CD45 
RA+ CD4 T Cells Requires CD4 and Lck But Not 
CXCR4 
  To investigate whether gp120 effect on 
CD45R0+/CD45RA+ CD4 T cell is due to ligation to CD4 
or CXCR4, we used either soluble CD4 or the CXCR4 in-
hibitor, AMD3100. Independent experiments verified the 
activity of AMD3100 by blocking SDF-induced chemotaxis 
(data not shown). As shown in Fig. (4A, B), inhibition of 
CD4 ligation by sCD4 [17] blocks the increase in double 
positive CD45R0+/CD45RA+ memory cells. Consistent with 
this observation, inhibition of Lck activity with PP2 inhibitor 
also blocks increase in CD45R0+/CD45RA+ CD4 T cell 
subset. Conversely inhibition of gp120-CXCR4 interaction 
with AMD3100 [17] does not block completely gp120 medi-
ated increase of CD45R0+/CD45RA+ CD4 T cells. There-
fore, our results demonstrate that gp120 ligation to CD4 and 
subsequent activation of Lck results in accumulation of dou-
ble positive CD45R0+/CD45RA+ memory CD4 T cells 
which subsequently and selectively undergo apoptosis in a 
CD4 dependent and CXCR4 independent manner. 
DISCUSSION 
  In the current report we have shown that gp120 treatment 
of activated CD4 T cells decreases the subset of single posi-
tive CD45R0+/CD45RA- CD4 T cells and increases the sub-
set of double positive CD45R0+/CD45RA+ CD4 T cells 
which selectively undergo apoptosis. These results imply the 
gp120 may play a role in depletion of memory CD45R0+/ 
CD45RA- CD4 T during HIV. 
  Previously, the CD45R0+/CD45RA+ subset of CD4 T 
cells was characterized as a transition from naïve to effector 
phenotype during CD4 priming [15, 18] with increased ex-
pression of activation markers [19, 20]. The generation of 
this subset can occur in two ways: (i) the transition of re-
cently activated of CD45RA+ T naïve cells to CD45R0+/ 
CD45RA+ phenotype [15, 21] and; (ii) re-expression of 
CD45RA isoform in the absence of Ag stimulation [15]. The 
fact that only few CD45R0+/CD45RA+ cells express mark-
ers of recently activated cells [19, 20] and upregulation of 
CD45RA+ (up to 10%) by CD45RO+/CD45RA- cells [15] 
suggest that gp120 rather upregulates CD45RA+ on single 
positive CD45RO+/CD45RA- memory CD4 T cells rather 
than promoting CD45RO expression on naïve CD4 T cells. 
Indeed, increase of double positive CD45RO+/CD45 RA+ 
CD4 T cells is followed by proportional decrease in 
CD45RO+/CD45RA- memory but not decrease in naïve 
CD45RO-/CD45RA+ CD4 T cells. 
  Others have shown that PBMC stimulated with staphylo-
coccal enterotoxin A (SEA) in the presence of V3-derived 
gp120 peptides results in increase of CCR5+/CXCR4+/ 
CD45RO+ CD4 T cells followed by increased levels of 
apoptosis [22]. Our findings are in good agreement with this 
observation: first, both results demonstrate the gp120 medi-
ated increase in transient state from naïve to activated CD4 T 
cells; second, both studies observe the increased apoptosis of 
activated CD4 T cells in the presence of gp120 or V3-
derived peptide. However, our results highlight that gp120 
priming of previously activated CD4 T cells reverses single 
positive CD45RO+/CD45RA- effector phenotype to double 
positive CD45RO+ /CD45RA+ transient phenotype. 
  The observation that double positive CD45R0+/CD45 
RA+ preferentially undergo apoptosis presents one potential 
scenario of how inappropriately activated CD4 T cells die 
during HIV disease, and why IL-2 augments this process [16]. 
It is of further interest that gp120 treatment results in apoptosis 
of CD27+/CD45R0+/CD45RA+ cells. In fact, CD27 expres-
sion is rapidly upregulated following TCR stimulation [23] 
and CD27 signaling is essential for survival of Ag-primed 
CD4 T cells [24]. Therefore, either the lack of antigen specific 
signaling or the lack of CD27 signaling may explain the in-
creased apoptosis of double positive CD45R0+/CD45RA+ 
following gp120 treatment. Finally, the observation that CD4 
ligation by gp120 and subsequent activation of Lck is required 
for generation of double positive CD45R0+/CD45RA+ CD4 T 
cells is of relevance and suggests that inhibitors of CD4-gp120 
interactions may reverse the expansion of double positive 
CD45R0+/CD45RA+ population and subsequent increased 
apoptosis during HIV infection. 
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Fig. (3). Gp120 increases subset of double positive CD45RA+/CD45RO+ CD4 T cells that undergo apoptosis. (A) Activated primary 
human CD4 T cells were treated with gp120 IIIIB and CD45RA+/CD45RO-, CD45RA-/CD45RO+ and double positive 
CD45RA+/CD45RO+ cells were quantified by flow cytometry. (B) Same as Fig. (3A) except that CD27 expression and Annexin-V positiv-
ity were measured by four color flow cytometry. The data is representative of three independent experiments. 
 
Fig. (4). CD4 and Lck are required for gp120 mediated increase of double positive CD45RA+/CD45RO+ CD4 T cells. (A) Acti-
vated primary human CD4 T cells were left untreated or were pre-treated with either Lck inhibitor, PP2 (5μM) or CXCR4 inhibitor, 
AMD3100 (2μM) or sCD4 (2μg/ml) followed by gp120. Then number of single positive CD45RA+/CD45RO-, CD45RA-/CD45RO+ and 
double positive CD45RA+/CD45RO+ cells were analyzed by flow cytometry. (B) The data represents three independent experiments as 
described above. P values were determined by Student’s paired t test. *=P<0.05 compared to gp120 alone. 
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